Plasma cell-free DNA analysis has emerged as a powerful liquid biopsy assay to assess circulating tumour DNA in response to cancer treatments. A new study shows that cell-free DNA can also inform on expansion kinetics and tumour-infiltration patterns in patients receiving chimeric antigen receptor T cells and, together with circulating tumour DNA, provides vivid prognostic insights into intratumoural dynamics.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Rent or buy this article
Get just this article for as long as you need it
$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Neelapu, S. S. et al. Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma. Blood Adv. 5, 4149–4155 (2021).
Larson, R. C. & Maus, M. V. Recent advances and discoveries in the mechanisms and functions of CAR T cells. Nat. Rev. Cancer 21, 145–161 (2021).
Haradhvala, N. J. et al. Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma. Nat. Med. 28, 1848–1859 (2022).
Good, Z. et al. Post-infusion CAR TReg cells identify patients resistant to CD19-CAR therapy. Nat. Med. 28, 1860–1871 (2022).
Deng, Q. et al. Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas. Nat. Med. 26, 1878–1887 (2020).
Frank, M. J. et al. Monitoring of circulating tumor DNA improves early relapse detection after axicabtagene ciloleucel infusion in large B-cell lymphoma: results of a prospective multi-institutional trial. J. Clin. Oncol. 39, 3034–3043 (2021).
Sworder, B. J. et al. Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas. Cancer Cell 41, 210–225.e5 (2023).
Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 377, 2531–2544 (2017).
Ennishi, D. et al. TMEM30A loss-of-function mutations drive lymphomagenesis and confer therapeutically exploitable vulnerability in B-cell lymphoma. Nat. Med. 26, 577–588 (2020).
Shouval, R. et al. Impact of TP53 genomic alterations in large B-cell lymphoma treated with CD19-chimeric antigen receptor T-cell therapy. J. Clin. Oncol. 40, 369–381 (2022).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
M.V.M. is an inventor in patents related to adoptive cell therapies, held by the Massachusetts General Hospital (some licensed to Promab) and the University of Pennsylvania (some licensed to Novartis); receives grant and research support from Kite Pharma; has served as a consultant for multiple companies involved in adoptive cell therapies; holds equity in 2SeventyBio, Century Therapeutics, Neximmune, Oncternal and TCR2; and is part of the board of directors for 2Seventy Bio. M.B.L. declares no competing interests.
Rights and permissions
About this article
Cite this article
Leick, M.B., Maus, M.V. Multiomics STEP up in correlative analysis of response to CAR T cells. Nat Rev Clin Oncol 20, 285–286 (2023). https://doi.org/10.1038/s41571-023-00742-5
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-023-00742-5
